Phase 1 Immune-mediated neurologic disorders Clinical Trials
2 recruitingPhase 1
What is a Phase 1 trial?
Phase 1 trials test a new treatment in a small group of people for the first time. The primary goal is to evaluate safety, determine a safe dosage range, and identify side effects. These studies typically enroll 20 to 80 participants.
Showing 1–2 of 2 trials
Completed
Phase 1
A Phase 1, Randomized, Open-Label Study of the Relative Bioavailability and Effect of Food on the Pharmacokinetics of a Novel Formulation of PRN2246 Compared to a Reference Formulation in Healthy Adult Participants
Immune-mediated neurologic disorders
Clinical Network Services (CNS) Pty Ltd14 enrolled1 locationACTRN12618001523291
Recruiting
Phase 1
A Phase I, Randomized, Double-Blind, Placebo-Controlled, Ascending Dose Study to Assess the Safety, Tolerability and Pharmacokinetics of Orally Administered PRN2246 in Healthy Volunteers
Immune-mediated neurologic disorders
Clinical Network Services98 enrolled1 locationACTRN12617001457336